F. Hoffmann-La Roche Ltd: Roche presents new and updated dat

Updated data from the phase III POLARIX study continue to demonstrate a statistically significant reduction in the risk of disease worsening or death for people with previously untreated diffuse large

Related Keywords

Lugano , Ticino , Switzerland , Japan , United States , Canada , America , American , Levi Garraway , Mabthera Rituxan , Gazyva Gazyvaro , Sabine Borngr , Gerard Tobin , Bruno Eschli , Venclexta Venclyxto , Birgit Masjost , Loren Kalm , Nathalie Altermatt , American Society Of Hematology , Genentech , Drug Administration , Roche Group , Head Of Global Product Development , Roche Group Media Relations , American Society , Annual Meeting , Chief Medical Officer , Global Product , Biologics License Application , Lugano Response Criteria , Dow Jones Sustainability Indices , Chugai Pharmaceutical , Previously Untreated Diffuse Largeb Cell , Hoffmann , Oche , Presents , Pdated , Data , Polivy , Reviously , Untreated , Diffuse , Barge , Fell , Lymphoma , 022 ,